In contrast, in preclinical models of MLL-AF9+ AML, bone marrow MSC downregulate Cxcl12 expression together with a variety of additional factors that support healthy hematopoiesis (Hanoun et al., 2014; Baryawno et al., 2019). This evidence concerns the gene CXCL12 and acute myeloid leukemia.